Targeting a specific receptor to treat autoimmune diseases and blood cancers
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
This study is looking at how a specific receptor related to prolactin might play a role in the development of certain blood cancers, especially in people with autoimmune disorders like lupus, to help find new ways to treat these conditions early on.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10889016 on NIH RePORTER |
What this research studies
This research investigates how the long isoform of the prolactin receptor may contribute to the development of high-risk B-cell malignancies, such as certain types of leukemia and lymphoma. By understanding the molecular mechanisms that lead to these cancers, particularly in patients with autoimmune disorders like systemic lupus erythematosus, the research aims to develop early interventions. The approach involves studying the effects of prolactin on B-cell proliferation and survival, which could lead to new treatment strategies. Patients may be involved in trials that explore these new therapeutic options.
Who could benefit from this research
Good fit: Ideal candidates for participation would include individuals with autoimmune disorders or high-risk B-cell malignancies.
Not a fit: Patients with non-B-cell malignancies or those without autoimmune conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for patients with autoimmune diseases and B-cell malignancies.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Swaminathan, Srividya — Beckman Research Institute/city of Hope
- Study coordinator: Swaminathan, Srividya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.